Neurosynaptic
Neurosynaptic Communications (NCPL) builds the ReMeDi® telemedicine platform and a portable 40+ test diagnostic kit, serving government primary health centers, CSR-funded foundations, and NGOs delivering rural healthcare across 12+ countries.
- Company typePrivate
- Founded2002
- HeadquartersBangalore, India
- Headcount101–250
- GTM typeB2B
- OfferingSoftware
What Neurosynaptic does
Neurosynaptic Communications Pvt. Ltd. (NCPL) is a Bangalore-based digital health and telemedicine company founded in 2002 by Sameer Sawarkar and Rajeev Kumar. The company develops and sells the ReMeDi® platform, a cloud-based telemedicine application that pairs with the ReMeDi® Kit, a portable 3.5 kg point-of-care diagnostic device integrating over 40 physiological and infectious-disease tests (ECG, blood pressure, SpO2, malaria, dengue, HIV, diabetes, lipids, fetal Doppler, hemoglobin). The platform supports patient registration, appointment scheduling, video consultations, e-prescriptions, referrals, comprehensive MIS reporting, multi-party video conferencing, and an offline mode for low-connectivity areas, with full alignment to India's Ayushman Bharat Digital Mission (ABDM) and e-Sanjeevani frameworks.
NCPL serves government primary health centers (PHCs) and health and wellness centers (HWCs), CSR-funded programs from corporate foundations (HCL, NSE, Bayer, Bill & Melinda Gates), and NGO-led healthcare delivery programs (World Health Partners, IPE Global), with deployments across 12+ countries and 2,500+ rural health centers. Its revenue model combines hardware sales of diagnostic kits, subscription-based licensing of the cloud platform, turnkey managed telemedicine services for PHC/HWC operators, and bespoke professional services. Distribution is direct-to-government via tenders, B2B to NGOs and foundations, and a franchise-style ReMeDi® Clinic model for rural micro-entrepreneurs. The company holds ISO 13485:2016, ISO 9001, ISO 27001, IEC 60601, and HIPAA-aligned certifications and has received recognition including a World Economic Forum Technology Pioneer designation and TIME Magazine feature.
The business is backed by a 2016 Series A from Indian Angel Network, HealthQuad, KOIS, and Axilor Ventures, and is led by founders Sameer Sawarkar (CEO) and Rajeev Kumar (COO), with a board including impact-investor directors Nagaraja Prakasam and Charles-Antoine Janssen (KOIS co-founder). NCPL positions itself as an indigenous, India-manufactured solution targeting last-mile rural healthcare delivery rather than as a pure software or AI-first platform play.
Neurosynaptic firmographics
Firmographics- Name
- Neurosynaptic
- Legal name
- Neurosynaptic Communications Pvt. Ltd.
- Website
- https://neurosynaptic.com
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Neurosynaptic Communications (NCPL) builds the ReMeDi® telemedicine platform and a portable 40+ test diagnostic kit, serving government primary health centers, CSR-funded foundations, and NGOs delivering rural healthcare across 12+ countries.
- Ownership category
- akta.pro rank
Neurosynaptic industry classification
Industry- Product category
- Telemedicine Solutions
- NAICS
- Medical and Diagnostic Laboratories (62151)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841), Services-Misc Health & Allied Services, Nec (8090)
- akta.pro primary industry
- Primary Care & General Medicine Virtual Care (HLALAAAA)
- akta.pro secondary industry
- Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL)
Keywords
Where Neurosynaptic is headquartered
LocationHeadquarters
- HQ city
- Bangalore
- HQ country
- India
- HQ region
- Asia
Offices1 record
Markets served
Neurosynaptic business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- ReMeDi® Kit Sales: Sale of portable diagnostic kits containing integrated diagnostic devices for point-of-care testing. Kits integrate over 40 diagnostic tests and are sold to government agencies, NGOs, and healthcare organizations.
- ReMeDi® Platform Licensing: Cloud-based telemedicine platform subscription and licensing for healthcare service delivery, supporting consultations, diagnostics, prescriptions, and referrals.
- Turnkey Telemedicine Services: End-to-end managed services for setting up and managing telemedicine-enabled clinics at PHCs and HWCs, including operational management, training, and support.
- Custom Healthcare Solutioning: Bespoke healthcare solutioning including flexible configuration of diagnostic kits, platform customizations, localization, and emerging technology integration.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Multi-year contract | ReMeDi® Kit - Standard Configuration |
| Subscription | Annual | ReMeDi® Platform - Cloud-based Telemedicine |
| Other | Multi-year contract | Turnkey Telemedicine Services |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels6 records
Neurosynaptic product offering
Product offeringCore offering
Neurosynaptic Communications (NCPL) develops and sells the ReMeDi® telemedicine platform and ReMeDi® Kit — a cloud-based healthcare application combined with a portable 3.5 kg diagnostic kit integrating over 40 point-of-care tests (ECG, blood pressure, SpO2, infectious diseases, diabetes, maternal health). The company sells the kits, licenses the cloud platform, and provides turnkey managed telemedicine services at government Primary Health Centers and Health and Wellness Centers, primarily targeting rural and underserved populations across India and 12+ countries.
Product overview
Neurosynaptic Communications Pvt. Ltd. (NCPL) offers the ReMeDi® Solutions Suite as its primary product portfolio, comprising three interconnected offerings: the ReMeDi® Platform (cloud-based telemedicine application), the ReMeDi® Kit (portable 3.5 kg diagnostic device with 40+ tests), and the ReMeDi® Solutions Suite (comprehensive implementation combining platform, kits, and bespoke services). The platform enables end-to-end healthcare delivery with workflow automation, offline functionality, and multi-platform compatibility (Windows and Android), while the kit provides point-of-care diagnostics for rural and underserved regions. The company also offers turnkey telemedicine services for PHCs, government program augmentation, and custom healthcare solutioning.
Differentiator
Problem solved
Functional benefit
Brands
- ReMeDi®: Neurosynaptic's flagship telemedicine and digital health platform brand, offering point-of-care diagnostics and telehealth solutions. ReMeDi® has evolved through multiple generations including the ReMeDi Nova model.
Products and services
- ReMeDi Platform
Quantifiable outcome
- 10,000+ direct beneficiaries per center per annum
- +3 more outcomes
Companies that use Neurosynaptic
Customer profileNamed customers6 records
Segments5 records
Ideal customer profiles5 records
Neurosynaptic technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
AI capability4 records
Feature6 records
Neurosynaptic partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- IPE Global Limited (USAID-backed SAMRIDH)coreEngaged for technical enhancements in ReMeDi, sales of 150 ReMeDi kits/solutions, and setup of 10 telemedicine centers across India for tier 2/3 towns under SAMRIDH-Healthcare Blended Finance Facility Project.
- Global Health LabscoreJoint development collaboration with premier research organization exemplifying leadership in global healthcare innovation.
- Saahas Waste Management Private LimitedminorPartnered with Saahas Waste Management Private Limited, a Producer Responsibility Organization Authorized by Central Pollution Control Board, for e-waste management and environmentally friendly disposal of end-of-life products.
- World Health PartnerscoreReMeDi® enabled delivery of care in thousands of interior villages of Uttar Pradesh and Bihar. NCPL adapted solutions to fit their service delivery structure.
- Jubilant Bhartia FoundationcoreSupplied multiple ReMeDi® sets of medical diagnostic devices performing satisfactorily in the field. CSR partnership for healthcare access.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Neurosynaptic competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Neurosynaptic social profiles
Digital presenceNeurosynaptic compliance and trust
Trust signalCompliance7 records
Neurosynaptic financial estimates
Financial estimateRevenue estimate
Valuation estimate
Neurosynaptic leadership team
Management profileNumber of profiles
Profiles11 records
Neurosynaptic funding detail
Funding detailFunding overview
Funding rounds1 record
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Neurosynaptic M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Neurosynaptic
What does Neurosynaptic do?
Neurosynaptic Communications (NCPL) develops and sells the ReMeDi® telemedicine platform and ReMeDi® Kit — a cloud-based healthcare application combined with a portable 3.5 kg diagnostic kit integrating over 40 point-of-care tests (ECG, blood pressure, SpO2, infectious diseases, diabetes, maternal health). The company sells the kits, licenses the cloud platform, and provides turnkey managed telemedicine services at government Primary Health Centers and Health and Wellness Centers, primarily targeting rural and underserved populations across India and 12+ countries.
Is Neurosynaptic a public or private company?
Neurosynaptic is a private company. It is classified as venture growth investor backed and is currently operating.
When was Neurosynaptic founded?
Neurosynaptic was founded in 2002. It employs 101 to 250 people.
Where is Neurosynaptic based?
Neurosynaptic is headquartered in Bangalore, India, in the Asia region.
How does Neurosynaptic make money?
Four revenue lines are on record. ReMeDi® Kit Sales are the primary driver. The others are reMeDi® Platform Licensing, turnkey Telemedicine Services and custom Healthcare Solutioning.
Does Neurosynaptic have an API?
No public API is recorded for Neurosynaptic.
What industry is Neurosynaptic in?
Neurosynaptic's product category is Telemedicine Solutions. Its primary akta.pro industry code is HLALAAAA, Primary Care & General Medicine Virtual Care, with a secondary code of HLAHACAL, Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers). Its NAICS code is 62151 and its SIC code is 3845.